Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection


Buti M., Tsai N., Petersen J., Flisiak R., GÜREL S. , Krastev Z., ...More

DIGESTIVE DISEASES AND SCIENCES, vol.60, no.5, pp.1457-1464, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 60 Issue: 5
  • Publication Date: 2015
  • Doi Number: 10.1007/s10620-014-3486-7
  • Title of Journal : DIGESTIVE DISEASES AND SCIENCES
  • Page Numbers: pp.1457-1464

Abstract

Background Long-term tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB) is associated with sustained viral suppression and regression of fibrosis and cirrhosis at year 5 (240 weeks) and no TDF resistance through 6 years (288 weeks).